Tribute Pharmaceuticals Canada (SLRXF) Inactive 10-Q2012 Q1 Quarterly report

Filed: 15 May 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: acquisition, Additionally, advance, advanced, agent, aggregate, agreed, American, approval, approved, balance, Bezalip, Bloom, borrowed, budget, Burton, Cambia, clarified, closed, closing, collectively, comprised, consolidated, creating, Daraprim, death, dermatology, disability, divided, Drug, ehf, emerging, employed, expand, extended, extensive, facility, FDA, footprint, forecast, geographical, globally, Group, Health, healthcare, incremental, indefinite, initial, integration, internationally, July, key, largest, launch, Libor, licensor, LLC, loan, marketplace, mature, maximize, medical, meeting, mentioned, MidCap, MycoVa, North, obligation, Ontario, opportunity, originally, Ottawa, owing, pain, payable, pharmacovigilance, portfolio, presence, primary, promote, promotion, PTC, ranging, receipt, reclassified, register, regulatory, remuneration, security, select, senior, set, significantly, simplified, Soriatane, specialty, SR, submission, team, thereof, Toronto, tranche, Tribute, twofold, UNREGISTERED, urology, USA, VOTE, world

Removed: advisory, allocate, allocation, alternative, application, appointment, arrangement, assisted, assurance, began, bladder, Board, broad, broadly, building, cancelled, cancer, carry, cease, CEO, challenging, commercialization, commissioned, consultant, continue, contractual, core, debt, declining, decrease, decreased, default, demonstrate, developed, developing, diagnostic, differential, dilution, discussed, entered, equipment, final, focused, founded, framework, fully, fund, funding, heading, hierarchy, high, IC, ii, iii, improve, inception, injection, invest, involved, licensee, Liquidity, locating, Matritech, measure, measuring, minimize, minimum, monitoring, niche, office, operating, orderly, overview, people, percentage, permanent, permit, permitted, planning, polysaccharide, presently, President, production, pursue, quality, quantity, realization, reduce, refer, registration, regular, require, residual, resulting, retained, retirement, return, salaried, seek, seeking, strategy, supply, technology, test, transfer, true, undeterminable, vacation, vested, warehouse, Watson

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SLRXF similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 (AS ADOPTED

PURSUANT TO SECTION 906 OF THE

SARBANES-OXLEY ACT OF 2002)

In connection with the quarterly report of Stellar Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2012 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Scott Langille, Chief Financial Officer, certify to my knowledge and in my capacity as an officer of the Company, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and,

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

Date: May 15, 2012

	/s/ Scott Langille
	Scott Langille
	Chief Financial Officer
	(Principle Financial Officer)